肿瘤浸润免疫细胞CD38表达对淋巴结转移食管鳞状细胞癌预后的影响

doi:10.3969/j.issn.1006-7795.2025.02.006

首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (2): 210-215.doi: 10.3969/j.issn.1006-7795.2025.02.006

• 临床研究与方法学应用进展 • 上一篇下一篇

肿瘤浸润免疫细胞CD38表达对淋巴结转移食管鳞状细胞癌预后的影响

石峰¹，赵艳杰²，高颖¹，宋清坤^3*

1.首都医科大学附属北京世纪坛医院病理科，北京 100038；2.首都医科大学附属北京世纪坛医院肿瘤内科，北京 100038；3.首都医科大学附属北京佑安医院生物医学信息中心，北京 100069

收稿日期:2024-11-18 出版日期:2025-04-21 发布日期:2025-04-14
通讯作者: 宋清坤 E-mail:songqingkun@ccmu.edu.cn
基金资助:
北京市属医院科研培育项目（PX2021031）。

Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis

Shi Feng¹, ZhaoYanjie², Gao Ying¹, Song Qingkun^3*

1.Department of Pathology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;2.Department of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China;3.Department of Biomedical Information Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Received:2024-11-18 Online:2025-04-21 Published:2025-04-14
Supported by:
This study was supported by Beijing Municipal Administration of Hospitals Incubating Program（PX2021031）.

摘要/Abstract

摘要： 目的探讨CD38对食管鳞状细胞癌（esophageal squamous cell carcinoma，ESCC）肿瘤免疫微环境及临床病理的影响。方法对2015年至2018年在首都医科大学附属北京世纪坛医院进行食管切除术的142例ESCC患者进行了回顾性队列研究。评估患者的临床病理特征、肿瘤组织内CD38、CD4、CD8、Ki-67、程序性细胞死亡配体1 （programmed cell death ligand 1, PD-L1）和程序性细胞死亡受体1 （programmed cell death 1, PD-1）的表达情况。结果在有淋巴结转移的ESCC患者中，CD38的表达率与总生存期有显著相关性（P=0.037），低表达组和高表达组患者的中位生存期分别为14个月和38个月。未经调整和调整的高CD38表达风险比分别为0.46（95%CI： 0.21~0.98）和0.32（95%CI： 0.13~0.76）。CD38的表达率与肿瘤细胞PD-L1表达呈负相关。结论对于有淋巴结转移的ESCC患者来说，CD38高表达与更好的生存率相关。

关键词: 食管鳞状细胞癌, CD38, 肿瘤浸润免疫细胞, 免疫微环境, 程序性细胞死亡配体1

Abstract: Objective To investigate the prognostic effect of CD38 in patients with esophageal squamous cell carcinoma patients (ESCC). Methods A retrospective cohort study with 142 ESCC patients was performed. The clinicopathological features and expression of CD38, CD4, CD8, Ki-67, programmed cell death ligand 1(PD-L1) and programmed cell death 1(PD-1) in tumor and immune cells were evaluated. Results Among ESCC patients with lymph node metastasis, the expression of CD38 had a significant association with the overall survival (P=0.037). The median overall survival was 14 months and 38 months among patients with low and high expression of CD38, respectively. The crude and adjusted hazard ratio of high CD38 expression was 0.46 (95%CI： 0.21-0.98) and 0.32 (95%CI： 0.13-0.76) respectively. The expression of CD38 had a negative correlation with PD-L1 expressed in tumor cells. Conclusion The high expression of CD38 was associated with a better survival for ESCC with lymph node metastasis.

Key words: esophageal squamous cell carcinoma, CD38, tumor-infiltrating immune cells, immune microenvironment, programmed cell death ligand 1

中图分类号:

R735

石峰, 赵艳杰, 高颖, 宋清坤. 肿瘤浸润免疫细胞CD38表达对淋巴结转移食管鳞状细胞癌预后的影响[J]. 首都医科大学学报, 2025, 46(2): 210-215.

Shi Feng, ZhaoYanjie, Gao Ying, Song Qingkun. Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis[J]. Journal of Capital Medical University, 2025, 46(2): 210-215.

参考文献

［1］刘润泽, 常栋, 李博闻. 食管鳞癌免疫治疗的临床进展［J］. 中华肿瘤防治杂志, 2021, 28 (13): 1028－1032.
［2］刘淑君, 苗浩, 王颖, 等. PD-1抑制剂联合化疗治疗晚期食管鳞状细胞癌的疗效评估及预后分析［J］. 中华肿瘤防治杂志, 2023, 30 (7): 406-411，429.
［3］Konen J M, Fradette J J, Gibbons D L. The good, the bad and the unknown of CD38 in the metabolic microenvironment and immune cell functionality of solid tumors［J］. Cells, 2019, 9(1): 52.
［4］Morandi F B, Airoldi I, Marimpietri D, et al. CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies［J］. Cells, 2019, 8(12): 1527.
［5］Wo Y J, Gan A S P, Lim X, et al. The roles of CD38 and CD157 in the solid tumor microenvironment and cancer immunotherapy［J］. Cells, 2019, 9(1): 26.
［6］贺正希, 刘惺, 周艳宏. CD38在临床肿瘤治疗中作用的研究进展［J］. 中南大学学报:医学版, 2022, 47(7): 952－959.
［7］Chen L M, Diao L X, Yang Y B, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade［J］. Cancer Discov, 2018, 8(9): 1156－1175.
［8］Zhang M, Yang J, Zhou J, et al. Prognostic values of CD38⁺CD101⁺PD1⁺CD8⁺ T cells in pancreatic cancer［J］. Immunol Invest, 2019, 48(5): 466－479.
［9］Debashree B, Soumya M, Swadeep K S, et al. Intratumoral PD1⁺CD38⁺Tim3⁺CD8⁺T cells in pre-BCG tumor tissues are associated with poor responsiveness to BCG immunotherapy in patients with non-muscle invasive bladder cancer［J］. Cells, 2023: 1939.
［10］Liu X, Grogan T R, Hieronymus H, et al. Low CD38 identifies progenitor-like inflammation-associated luminal cells that can initiate human prostate cancer and predict poor outcome［J］. Cell Rep, 2016, 17(10): 2596－2606.
［11］Lam J H, Ng H H M, Lim C J, et al. Expression of CD38 on macrophages predicts improved prognosis in hepatocellular carcinoma［J］. Front Immunol, 2019, 10: 2093.
［12］Yeong J, Lim J C T, Lee B, et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer［J］. Front Immunol, 2018, 9: 1209.
［13］Sahoo D, Wei W, Auman H, et al. Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancer［J］. Oncotarget, 2018, 9(5): 6550－6561.
［14］Li Y, Lu Z L, Che Y, et al. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma［J］. Oncoimmunology, 2017, 6(11): e1356147.
［15］Dwivedi S, Rendón-Huerta E P, Ortiz-Navarrete V, et al. CD38 and regulation of the immune response cells in cancer［J］. J Oncol, 2021, 2021: 6630295.
［16］Marie J Y R, Masayuki O, Justine J W S, et al. CD38 marks the exhausted CD8+tissue-resident memory T cells in hepatocellular carcinoma［J］. Front Immunol, 2023, 14: 1182016.
［17］Heimes A S, Riedel N, Almstedt K, et al. Prognostic impact of CD38-and IgκC-positive tumor-infiltrating plasma cells in triple-negative breast cancer［J］. Int J Mol Sci, 2023, 24(20): 15219.
［18］Mimura K Y L, Ujiie D, Hayase S, et al. Immunotherapy for esophageal squamous cell carcinoma:a review［J］. Fukushima J Med Sci, 2018, 64(2): 46－53.
［19］Liu D, Xu H P, Shih C, et al. T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction［J］. Nature, 2015, 517(7533): 214－218.
［20］孙小虎, 王璐, 白静慧, 等. 晚期肝癌免疫微环境CD38表达水平与PD-1抑制剂疗效相关性分析［J］. 肝脏, 2023, 28(1): 75－78, 94.
［21］Chatterjee S, Daenthanasanmak A, Chakraborty P, et al. CD38-NAD⁺axis regulates immunotherapeutic anti-tumor T cell response［J］. Cell Metab, 2018, 27(1): 85－100.e8.

[1]	杜风, 徐瑞, 赵梦冉, 冀旭, 苏珈仪, 邱煜婷, 朱圣韬, 吴静, 李鹏, 张澍田. SOX4在幽门螺杆菌介导的胃黏膜上皮异型增生中的作用及机制研究[J]. 首都医科大学学报, 2025, 46(4): 644-653.
[2]	刘娟, 张政, 李鹏. 自身免疫性胃炎并发胃早癌的临床特征分析[J]. 首都医科大学学报, 2025, 46(4): 670-675.
[3]	高天博, 葛洋, 安广宇, 姚健楠, 蒋玉良, 刘贺书, 闫锐. 分子伴侣Cosmc或T-合酶缺失介导的异常O-糖基化调控结肠癌外泌体中微小RNA的表达[J]. 首都医科大学学报, 2025, 46(3): 401-409.
[4]	尹雪, 于明航, 王玺, 陈京龙. 肝癌中SWI/SNF复合物突变与免疫检查点抑制剂治疗应答反应的研究进展[J]. 首都医科大学学报, 2023, 44(5): 768-774.
[5]	肖泽儒, 闫锐, 梁紫葳, 葛洋, 安广宇. 苯并芘上调食管鳞癌环氧化酶-2表达诱导M2型巨噬细胞浸润增加机制[J]. 首都医科大学学报, 2023, 44(5): 753-761.
[6]	谭宇博, 苏卜伊努尔·吐尔洪, 黄静, 张婷婷, 刘俊杰, 沙娅·玛哈提. miR-150靶向调控IGF2BP2对肝癌恶性表型的影响机制[J]. 首都医科大学学报, 2023, 44(5): 762-767.
[7]	宁婷婷, 王照情, 张楠, 朱圣韬. ACE2在结肠癌中表达的临床意义及结肠癌细胞对以ACE2为受体的三种人冠状病毒的易感性分析[J]. 首都医科大学学报, 2023, 44(4): 663-668.
[8]	郭继红, 朱宁, 葛洋, 安广宇. 晚期胰腺癌患者的临床特征及预后分析[J]. 首都医科大学学报, 2023, 44(3): 501-506.
[9]	郭春梅, 刘红, 焦月, 张倩, 王沧海, 王亚丹, 蔺武, 魏南, 张澍田, 吴静. 结直肠癌术后患者异时性进展期腺瘤风险筛查模型的构建及验证[J]. 首都医科大学学报, 2023, 44(2): 295-301.
[10]	孙婧, 史幼梧, 杜丰, 杨颖, 孙志伟, 余靖, 肖艳洁, 张晓东, 贾军. 消化道肿瘤免疫相关不良事件的临床分析[J]. 首都医科大学学报, 2023, 44(2): 343-350.
[11]	李荣雪, 张倩, 邢洁, 孙秀静, 李鹏, 焦月, 张澍田. 超声内镜对早期结直肠癌的诊断价值分析[J]. 首都医科大学学报, 2023, 44(1): 126-130.
[12]	邵琳琳, 朱思莹, 邢洁, 武珊珊, 朱圣韬, 张澍田. 原发性胃肠道淋巴瘤的临床特征和内镜特点分析[J]. 首都医科大学学报, 2022, 43(2): 205-209.
[13]	李雪, 邢洁, 张倩, 李鹏, 吕富靖, 张澍田. 窄带成像技术联合放大内镜JES分型对早期食管癌的诊断价值[J]. 首都医科大学学报, 2022, 43(2): 210-215.
[14]	孙婧, 史幼梧, 贾军, 杨颖, 孙志伟, 杜丰, 余靖, 肖艳洁, 张晓东. 血液炎症相关指标在晚期胰腺癌中的预后价值[J]. 首都医科大学学报, 2022, 43(2): 299-304.
[15]	孙灿, 邢洁, 张希, 孙秀静, 张澍田. 内镜下黏膜剥离术治疗低位直肠早癌的临床分析[J]. 首都医科大学学报, 2022, 43(1): 34-37.

肿瘤浸润免疫细胞CD38表达对淋巴结转移食管鳞状细胞癌预后的影响

Effect of CD38 expression of tumor-infiltrating immune cells on the prognosis of esophageal squamous cell carcinoma with lymph node metastasis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价